Staphylococcus aureus pneumonia is associated with high mortality, irrespective of antibiotic susceptibility. Up to six cytolytic toxins are produced by S. aureus: alpha-hemolysin (Hla) and the five bi-component leukocidins (HlgAB, HlgCB, LukED, LukSF, and LukGH/LukAB) that are important for pathogenesis. We previously described two human IgG1 monoclonal antibodies (mAbs), ASN-1 and ASN-2, that in combination (as ASN100) neutralize these six toxins. Unlike mice, rabbits are sensitive to all of these toxins and therefore, the prophylactic efficacy and key pharmacokinetic (PK) parameters of ASN100 were determined in this species. Since antibodies lack anti-toxin mechanisms and are even reported to upregulate toxin production of S. aureus, we also evaluated the therapeutic synergy of ASN100 with different antibiotics in a rabbit model of lethal MRSA pneumonia.

**Methods**

**Animals:** All studies were performed in ~3kg male New Zealand White rabbits.

**Pharmacokinetics:** Serum and bronchoalveolar lavage fluid (BALF) samples were serially collected from uninfected and S. aureus infected animals immunized with 40 mg/kg of ASN100. Total human and rabbit IgG concentrations were determined by sandwich ELISA using human or rabbit specific capture and detection antibodies. ASN-1 and ASN-2 (free drug) concentrations were measured with anti-epitope mAbs. Urea levels in BALF and serum were quantified in ELISA and used to determine antibody concentrations in epithelial lining fluid (ELF).

**Prophylaxis:** Animals were passively immunized with ASN100 at five dose levels between 0.08 to 20 mg/kg total mAb (ASN-1 and ASN-2 at 1:1 ratio), 24 hours prior to intratracheal challenge with lethal doses of USA300 CA-MRSA, USA100 HA-MRSA, or two MSSA strains. Control animals were treated with placebo. Survival was monitored for 7 days post challenge. Alternatively, animals were sacrificed at 12 hours post challenge and gross necropsy as well as microbiological analyses were performed.

**Therapy:** Animals were intratracheally infected with a lethal dose of a USA300 CA-MRSA strain. Two hours post infection, animals were treated with individually protective doses of cloxacillin and/or ASN100. Study drugs were administered at doses and routes stated in the respective panels. Survival of animals was monitored for 7 days post challenge.

**Pharmacokinetics of ASN100 in non-infected and infected rabbits**

Serum and ELF concentrations of rabbits immunized with 40 mg/kg of ASN100 were determined at different time points after mAb administration. In challenge studies, lethal doses of USA300 CA-MRSA (LAC) or MSSA (ST2) strains were administered intratracheally 24 hours post dosing.

**Clearance of S. aureus from the lungs of ASN100 protected rabbits**

Bacterial lung burden was determined in rabbits immunized with 40 mg/kg of ASN100 and challenged with lethal doses of a USA300 CA-MRSA or an MSSA 24 hours after mAb administration.

**Prophylactic efficacy in rabbit pneumonia models**

24 hours post immunization with different doses of ASN100 or placebo rabbits were intratracheally infected with a lethal inoculum of S. aureus. Survival was monitored for 7 days post challenge.

**ASN100 dose-dependent effect on lung pathology**

Three doses of ASN100 (1.25-20 mg/kg) were evaluated for reduction of lung pathology in infected animals sacrificed 12 hours post-challenge by a USA300 CA-MRSA (LAC) strain.

**ASN100 elicits therapeutic efficacy against a USA300 CA-MRSA in rabbits, which can be improved by cloxacillin**

Rabbits were intratracheally infected with a USA300 CA-MRSA strain and treated with ASN100 (single i.v. bolus) and/or cloxacillin (intermittent i.v. infusion q8h for 48h). Survival was monitored for 7 days post challenge.

**Conclusions**

- PK-analyses of ASN100 in BALF from uninfected and S. aureus infected animals confirmed efficient mAb penetration into lung ELF within the first two days following intravenous administration; ASN100 ELF levels reached 50% of the serum concentrations by 24 hours, and peak levels by 48 hours post-dosing in uninfected rabbits.
- ASN100 serum and ELF levels were not depleted in the lung of rabbits intratracheally infected with S. aureus despite the presence of bacteria for up to 3 days post challenge.
- ASN100 elicited high prophylactic efficacy against all S. aureus strains tested in lethal rabbit models of pneumonia irrespective of antibiotic susceptibility (MRSA and MSSA) and toxin expression (both pvl- and pvl+) profiles of the challenge strains.
- Full protection against the two MRSA strains was achieved by 5 mg/kg ASN100 (2.5 mg/kg each mAb), while the two MSSA strains required a higher dose (20 mg/kg).
- Reduction of bacterial counts, lung edema rate as well as macroscopic lung scores of infected animals were most pronounced with the 20 mg/kg ASN100 dose.
- In therapeutic models, ASN100 showed significant efficacy alone, with doses as low as 2 mg/kg protecting 67% of the rabbits.
- Surprisingly, the combination of ASN100 with cloxacillin further improved the therapeutic efficacy, even against the USA300 CA-MRSA strain.
- ASN100 is currently being evaluated in a Phase 2 clinical trial to prevent S. aureus pneumonia in mechanically ventilated patients.

**Acknowledgements:** We thank Sandrine Albac, Davy Hayez, Karin Groß, Barbara Maierhofer and Susanne Weber for their technical support.

**Disclosure:** All authors are employees and shareholders in the companies performing this work.

**Contact:** Lukas Stulik, Arsán Biosciences GmbH, Helmut-Qualtlinger-Gasse 2, 1030 Vienna, Austria. E-mail: lukas.stulik@arsanis.com